Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Currently #24 of 43 (!!!!) at clinicaltrialsdotgov...
A relatively large p2 NCI-sponsored trial, enrolling 150...presumably in addition to the RCC trial EXEL is planning later this year. I haven't but barely glanced at the other new trial announcements, but we've gained another 10% in clinical mojo this week alone!!!